Flagship Pioneering

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

CIBO Technologies, Inc. specializes in developing advanced software products that model and simulate agricultural ecosystems to enhance sustainability and productivity in farming. Its offerings include Continuum DB, a distributed database for spatio-temporal modeling, and BarnCAT, a toolkit for analyzing plant and soil sciences. Additionally, CIBO provides WhetherRain, a stochastic weather generator for detailed weather simulations, and DirtPatch, a platform focused on environmental reconstruction. Its Land Intelligence platform delivers insights on agricultural parcels, catering to a diverse clientele in sectors such as farm services, agribusiness, and financial services. By leveraging data science and computational agronomy, CIBO aims to improve grower outcomes and drive the adoption of sustainable agricultural practices, contributing to climate change mitigation and food system resilience. Founded in 2014 and headquartered in Cambridge, Massachusetts, CIBO also has offices in Saint Louis, East Lansing, and Minneapolis.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Invaio Sciences, Inc. is a technology company based in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Founded in 2016, the company focuses on harnessing the potential of interdependent natural systems to address significant challenges in agriculture, nutrition, and the environment. Invaio Sciences is dedicated to developing innovative technologies grounded in scientific research, aiming to implement transformative solutions that positively impact agriculture, human health, animal nutrition, and animal health.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

Ohana Biosciences is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing innovative molecular techniques aimed at enhancing reproductive health, particularly by focusing on sperm biology rather than egg biology. Ohana's products are designed to improve sperm quality and function, thereby addressing infertility and preventing inherited diseases. Additionally, the company is working on a long-acting, reversible, and non-hormonal male contraceptive. Through its advancements in reproductive medicine, Ohana Biosciences aims to empower individuals and couples to have children on their own terms, while also striving to reduce pregnancy complications.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Invaio Sciences, Inc. is a technology company based in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Founded in 2016, the company focuses on harnessing the potential of interdependent natural systems to address significant challenges in agriculture, nutrition, and the environment. Invaio Sciences is dedicated to developing innovative technologies grounded in scientific research, aiming to implement transformative solutions that positively impact agriculture, human health, animal nutrition, and animal health.

Cygnal Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing drugs that manipulate exoneural biology to address cancer, immunological diseases, and regenerative processes. Founded in 2016 by Flagship Pioneering within the VentureLabs innovation foundry, Cygnal harnesses advanced neurotechnology to explore and discover new dimensions of neural function. The company aims to create innovative therapeutic options by leveraging its unique approach to understanding and altering the interactions between the nervous system and various biological processes.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Evelo Biosciences is a biotechnology company focused on discovering and developing oral biologics known as monoclonal microbials for the treatment of inflammatory diseases and cancer. These innovative medicines are designed to modulate systemic immunology through direct interactions with human cells in the gut, offering potential applications across a wide range of conditions, including autoimmune and neuroinflammatory diseases, as well as various cancers. Evelo's lead product, EDP1815, is currently undergoing clinical trials for psoriasis and atopic dermatitis, while other candidates are in preclinical stages for conditions such as psoriatic arthritis, asthma, and colorectal cancer. Founded in 2014 and based in Cambridge, Massachusetts, Evelo aims to enhance the efficiency and effectiveness of drug discovery by leveraging naturally occurring microbial entities with defined therapeutic effects.

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.

CIBO Technologies, Inc. specializes in developing advanced software products that model and simulate agricultural ecosystems to enhance sustainability and productivity in farming. Its offerings include Continuum DB, a distributed database for spatio-temporal modeling, and BarnCAT, a toolkit for analyzing plant and soil sciences. Additionally, CIBO provides WhetherRain, a stochastic weather generator for detailed weather simulations, and DirtPatch, a platform focused on environmental reconstruction. Its Land Intelligence platform delivers insights on agricultural parcels, catering to a diverse clientele in sectors such as farm services, agribusiness, and financial services. By leveraging data science and computational agronomy, CIBO aims to improve grower outcomes and drive the adoption of sustainable agricultural practices, contributing to climate change mitigation and food system resilience. Founded in 2014 and headquartered in Cambridge, Massachusetts, CIBO also has offices in Saint Louis, East Lansing, and Minneapolis.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at reducing the cost of producing clean water. Founded in 2008, it has developed a platform called Engineered Osmosis, which incorporates forward osmosis and a draw solution recovery technique to make salt water treatment more economical. The company focuses on providing integrated membrane systems for high recovery desalination, brine management, and zero liquid discharge solutions. Through its innovative technologies, Oasys Water addresses the global water crisis by promoting more efficient and sustainable resource utilization, enabling industries to enhance their operational efficiencies while minimizing environmental impact. In addition to its Boston headquarters, Oasys Water also has an office in Dubai.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Evelo Biosciences is a biotechnology company focused on discovering and developing oral biologics known as monoclonal microbials for the treatment of inflammatory diseases and cancer. These innovative medicines are designed to modulate systemic immunology through direct interactions with human cells in the gut, offering potential applications across a wide range of conditions, including autoimmune and neuroinflammatory diseases, as well as various cancers. Evelo's lead product, EDP1815, is currently undergoing clinical trials for psoriasis and atopic dermatitis, while other candidates are in preclinical stages for conditions such as psoriatic arthritis, asthma, and colorectal cancer. Founded in 2014 and based in Cambridge, Massachusetts, Evelo aims to enhance the efficiency and effectiveness of drug discovery by leveraging naturally occurring microbial entities with defined therapeutic effects.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, it is focused on discovering and developing innovative genome editing therapeutics to address a wide range of serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 technology, which employs a protein-RNA complex to target and modify specific DNA sequences for therapeutic purposes. Editas Medicine aims to translate its advanced genome editing technologies into human therapeutics that can provide precise and corrective molecular modifications to treat genetic disorders. With a strong foundation of patent filings and intellectual property, the company is positioned to advance its early findings into viable treatments for various diseases at the genetic level.

Joule Unlimited, Inc. is a company focused on producing infrastructure-compatible fuels using solar energy and waste carbon dioxide. Founded in 2007 and headquartered in Cambridge, Massachusetts, with an additional office in Los Angeles, the company utilizes photosynthetic microorganisms as living catalysts to convert CO2 directly into sustainable liquid fuels, such as diesel and ethanol. Joule Unlimited's innovative approach enables the recycling of greenhouse gases, turning them into valuable hydrocarbon fuels and contributing to renewable fuel and chemical production. Formerly known as Joule Biotechnologies, Inc., the company rebranded in 2010 to reflect its broader focus on sustainable energy solutions.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, it is focused on discovering and developing innovative genome editing therapeutics to address a wide range of serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 technology, which employs a protein-RNA complex to target and modify specific DNA sequences for therapeutic purposes. Editas Medicine aims to translate its advanced genome editing technologies into human therapeutics that can provide precise and corrective molecular modifications to treat genetic disorders. With a strong foundation of patent filings and intellectual property, the company is positioned to advance its early findings into viable treatments for various diseases at the genetic level.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

WikiCell Designs Inc., a Cambridge, Mass. and Paris, France-based company developing edible forms of food and beverage packaging.

Sesen Bio, Inc. is a late-stage clinical company focused on developing targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy designed for high-risk non-muscle invasive bladder cancer and is currently in phase 3 clinical trials. Another candidate, VB6-845d, aims to treat various EpCAM-positive solid tumors. Additionally, Sesen Bio is exploring combinations of Vicinium with other treatments, including Durvalumab for high-risk non-muscle invasive bladder cancer, and with AstraZeneca's checkpoint inhibitor for squamous cell carcinoma of the head and neck. The company has also partnered with Leiden University Medical Center to co-develop an imaging agent. Founded in 2008 and headquartered in Cambridge, Massachusetts, Sesen Bio was previously known as Eleven Biotherapeutics, Inc. before rebranding in May 2018.

Polatis is a company specializing in optical switching technology, established in 2005 through the merger of prominent optical technology firms from Cambridge, Massachusetts, and Cambridge, UK. The company focuses on developing optical layer connectivity software designed to manage and switch fiber-based optical networks. Polatis offers a range of products, including single- and multi-mode optical matrix switches, carrier optical monitor switches, and latching switches, aimed at enhancing the efficiency and performance of modern fiber networks.

Joule Unlimited, Inc. is a company focused on producing infrastructure-compatible fuels using solar energy and waste carbon dioxide. Founded in 2007 and headquartered in Cambridge, Massachusetts, with an additional office in Los Angeles, the company utilizes photosynthetic microorganisms as living catalysts to convert CO2 directly into sustainable liquid fuels, such as diesel and ethanol. Joule Unlimited's innovative approach enables the recycling of greenhouse gases, turning them into valuable hydrocarbon fuels and contributing to renewable fuel and chemical production. Formerly known as Joule Biotechnologies, Inc., the company rebranded in 2010 to reflect its broader focus on sustainable energy solutions.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Everyday Solutions, Inc. provides GPS-based vehicle tracking solutions designed for student transportation markets. It offers GPS-based vehicle and student tracking solutions to pupil transportation marketplace in the United States and Canada. The company provides real-time tracking solution insuring route compliance, driver safety compliance, student attendance tracking, automatic parent notifications, and management reporting. Everyday Solutions has strategic partnership with Sprint Nextel, Trapeze Software Group, VersaTrans Solutions, Transfinder, Orbit Software, EDULOG, and U.S. Computing. The company was founded in 2000 as Everyday Wireless, Inc. and changed its name to Everyday Solutions, Inc. in July 2008. Everyday Solutions, Inc. is headquartered in Concord, Massachusetts.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Joule Unlimited, Inc. is a company focused on producing infrastructure-compatible fuels using solar energy and waste carbon dioxide. Founded in 2007 and headquartered in Cambridge, Massachusetts, with an additional office in Los Angeles, the company utilizes photosynthetic microorganisms as living catalysts to convert CO2 directly into sustainable liquid fuels, such as diesel and ethanol. Joule Unlimited's innovative approach enables the recycling of greenhouse gases, turning them into valuable hydrocarbon fuels and contributing to renewable fuel and chemical production. Formerly known as Joule Biotechnologies, Inc., the company rebranded in 2010 to reflect its broader focus on sustainable energy solutions.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Polatis is a company specializing in optical switching technology, established in 2005 through the merger of prominent optical technology firms from Cambridge, Massachusetts, and Cambridge, UK. The company focuses on developing optical layer connectivity software designed to manage and switch fiber-based optical networks. Polatis offers a range of products, including single- and multi-mode optical matrix switches, carrier optical monitor switches, and latching switches, aimed at enhancing the efficiency and performance of modern fiber networks.

Carbon Design Systems, Inc. specializes in virtual prototype solutions for system-on-chip (SoC) designs, aiming to enhance the development, execution, and analysis of complex virtual system platforms. Their key offerings include Carbon SoC Designer Plus, which facilitates the creation and validation of virtual prototypes, and Carbon Model Studio, designed for the automatic generation and execution of hardware-accurate software models. The company also provides Carbon Performance Analysis Kits (CPAK), pre-built virtual reference platforms essential for optimizing performance elements like processors and memory controllers. Additionally, Carbon Design Systems supports system validation, software execution, and traffic analysis, while offering consulting, training, and integration services. Their solutions cater to systems, semiconductor, and intellectual property companies in sectors such as wireless communication, networking, and consumer electronics. Founded in 2002 and based in Acton, Massachusetts, Carbon Design Systems operates as a subsidiary of ARM Holdings plc.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at reducing the cost of producing clean water. Founded in 2008, it has developed a platform called Engineered Osmosis, which incorporates forward osmosis and a draw solution recovery technique to make salt water treatment more economical. The company focuses on providing integrated membrane systems for high recovery desalination, brine management, and zero liquid discharge solutions. Through its innovative technologies, Oasys Water addresses the global water crisis by promoting more efficient and sustainable resource utilization, enabling industries to enhance their operational efficiencies while minimizing environmental impact. In addition to its Boston headquarters, Oasys Water also has an office in Dubai.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

BG Medicine, Inc. is a life sciences company based in Waltham, Massachusetts, focused on the development and commercialization of diagnostic products aimed at guiding the treatment of patients with heart failure and related disorders. The company offers the BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 levels in serum or plasma, and the CardioSCORE Test, a multi-analyte blood test designed to assess the near-term risk of atherothrombotic cardiovascular events, such as heart attacks and strokes. BG Medicine has established partnerships with several prominent firms, including Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., to develop automated versions of its tests and related assay kits. Founded in 2000, BG Medicine was previously known as Beyond Genomics, Inc. and rebranded in 2004.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Carbon Design Systems, Inc. specializes in virtual prototype solutions for system-on-chip (SoC) designs, aiming to enhance the development, execution, and analysis of complex virtual system platforms. Their key offerings include Carbon SoC Designer Plus, which facilitates the creation and validation of virtual prototypes, and Carbon Model Studio, designed for the automatic generation and execution of hardware-accurate software models. The company also provides Carbon Performance Analysis Kits (CPAK), pre-built virtual reference platforms essential for optimizing performance elements like processors and memory controllers. Additionally, Carbon Design Systems supports system validation, software execution, and traffic analysis, while offering consulting, training, and integration services. Their solutions cater to systems, semiconductor, and intellectual property companies in sectors such as wireless communication, networking, and consumer electronics. Founded in 2002 and based in Acton, Massachusetts, Carbon Design Systems operates as a subsidiary of ARM Holdings plc.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating serious and rare diseases. Based in Cambridge, Massachusetts, the company focuses on developing novel biotherapeutics that modulate growth factors related to bone, muscle, fat, and vascular health. Its product portfolio includes luspatercept-aamt, marketed as REBLOZYL, for treating anemia in adult patients with beta-thalassemia, and candidates such as Sotatercept for pulmonary arterial hypertension. Additionally, Acceleron is advancing ACE-083, a neuromuscular treatment currently in Phase II trials for Charcot-Marie-Tooth disease. The company collaborates with partners like Celgene Corporation and Fulcrum Therapeutics to develop therapies targeting specific pathways in pulmonary diseases. Founded in 2003, Acceleron Pharma continues to focus on creating innovative treatments for conditions such as cancer-related bone loss, muscle degeneration, and metabolic disorders.

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines. Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients. Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands. Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates. In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

Everyday Solutions, Inc. provides GPS-based vehicle tracking solutions designed for student transportation markets. It offers GPS-based vehicle and student tracking solutions to pupil transportation marketplace in the United States and Canada. The company provides real-time tracking solution insuring route compliance, driver safety compliance, student attendance tracking, automatic parent notifications, and management reporting. Everyday Solutions has strategic partnership with Sprint Nextel, Trapeze Software Group, VersaTrans Solutions, Transfinder, Orbit Software, EDULOG, and U.S. Computing. The company was founded in 2000 as Everyday Wireless, Inc. and changed its name to Everyday Solutions, Inc. in July 2008. Everyday Solutions, Inc. is headquartered in Concord, Massachusetts.

Ensemble Therapeutics Corporation is engaged in the discovery and development of small molecule therapies aimed at treating cancer and other serious diseases. The company focuses on creating innovative therapies, particularly in the field of immuno-oncology, targeting mechanisms such as Indoleamine 2, 3-dioxygenase 1 (IDO-1) and components of the ubiquitin proteasome system. Its pipeline includes treatments that inhibit apoptosis-promoting proteins, which can prevent tumor cell death, as well as targeting Cyclophilins that aid in protein folding. Founded in 2002 and based in Cambridge, Massachusetts, Ensemble Therapeutics aims to provide safe and effective treatment options by addressing previously inaccessible drug targets. The company changed its name from Ensemble Discovery Corporation in June 2010.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Carbon Design Systems, Inc. specializes in virtual prototype solutions for system-on-chip (SoC) designs, aiming to enhance the development, execution, and analysis of complex virtual system platforms. Their key offerings include Carbon SoC Designer Plus, which facilitates the creation and validation of virtual prototypes, and Carbon Model Studio, designed for the automatic generation and execution of hardware-accurate software models. The company also provides Carbon Performance Analysis Kits (CPAK), pre-built virtual reference platforms essential for optimizing performance elements like processors and memory controllers. Additionally, Carbon Design Systems supports system validation, software execution, and traffic analysis, while offering consulting, training, and integration services. Their solutions cater to systems, semiconductor, and intellectual property companies in sectors such as wireless communication, networking, and consumer electronics. Founded in 2002 and based in Acton, Massachusetts, Carbon Design Systems operates as a subsidiary of ARM Holdings plc.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating serious and rare diseases. Based in Cambridge, Massachusetts, the company focuses on developing novel biotherapeutics that modulate growth factors related to bone, muscle, fat, and vascular health. Its product portfolio includes luspatercept-aamt, marketed as REBLOZYL, for treating anemia in adult patients with beta-thalassemia, and candidates such as Sotatercept for pulmonary arterial hypertension. Additionally, Acceleron is advancing ACE-083, a neuromuscular treatment currently in Phase II trials for Charcot-Marie-Tooth disease. The company collaborates with partners like Celgene Corporation and Fulcrum Therapeutics to develop therapies targeting specific pathways in pulmonary diseases. Founded in 2003, Acceleron Pharma continues to focus on creating innovative treatments for conditions such as cancer-related bone loss, muscle degeneration, and metabolic disorders.

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines. Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients. Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands. Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates. In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.

Calpurnia Corporation provides intelligent video analysis solutions for the retail industry. It offers Video Investigator software for loss prevention and store intelligence solutions. The company's software protects people and assets in support of loss prevention, customer safety, and compliance policy efforts. Calpurnia's professional services offer a range of consulting, training, and implementation services. The company was founded in 2002 as IntelliVid Corporation and changed its name to Calpurnia Corporation in July 2008. The company is headquartered in Cambridge, Massachusetts. As of July 16, 2008, Calpurnia Corporation operates as a subsidiary of Tyco International Ltd.

As of September 22, 2009, Interactive Supercomputing, Inc. was acquired by Microsoft Corporation. Interactive Supercomputing, Inc. develops and commercializes Star-P, an interactive parallel computing platform for automatic parallelization and interactive execution of desktop simulation applications in biomedical, financial, and government laboratory research sectors. Its Star-P software platform allows users performing scientific, engineering, or analytical computation on array or matrix-based data to use parallel architectures, such as multi-core workstations, multi-processor systems, distributed memory clusters, and/or utility/cloud-based environments. The company also offers customer support and professional services, as well as application consulting, and enterprise installation and training services. It offers its products through authorized resellers in the United States and internationally. The company was founded in 2004 and is headquartered in Waltham, Massachusetts.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.

Integrated Development Enterprise, Inc. develops project and product portfolio management solutions. It offers IDeWeb solutions, including integrated applications and professional services to Web-enable product portfolio management in enterprise market. The company’s solutions enable companies to automate and integrate processes and information for business decision-making in product development. Integrated Development Enterprise, Inc. was founded in 1998 and is based in Concord, Massachusetts.

Carbon Design Systems, Inc. specializes in virtual prototype solutions for system-on-chip (SoC) designs, aiming to enhance the development, execution, and analysis of complex virtual system platforms. Their key offerings include Carbon SoC Designer Plus, which facilitates the creation and validation of virtual prototypes, and Carbon Model Studio, designed for the automatic generation and execution of hardware-accurate software models. The company also provides Carbon Performance Analysis Kits (CPAK), pre-built virtual reference platforms essential for optimizing performance elements like processors and memory controllers. Additionally, Carbon Design Systems supports system validation, software execution, and traffic analysis, while offering consulting, training, and integration services. Their solutions cater to systems, semiconductor, and intellectual property companies in sectors such as wireless communication, networking, and consumer electronics. Founded in 2002 and based in Acton, Massachusetts, Carbon Design Systems operates as a subsidiary of ARM Holdings plc.

Extraprise, Inc. operates as a systems integrator and business process outsourcer in customer management. Its insight-to-interaction solutions combine data management, business insight, demand generation, and customer management. The company was formed in 1997 and is headquartered in Boston, Massachusetts, with additional offices in the United States and Europe.

Ellacoya Networks specializes in providing Broadband Service Optimization solutions that utilize deep packet inspection (DPI) technology, allowing broadband service providers to enhance their Internet offerings. The company’s hardware platforms, such as the e30 and e100, along with a comprehensive suite of software applications, enable service providers to identify subscribers and manage applications on an individual basis. This capability helps improve performance, boost customer satisfaction, and facilitate the delivery of revenue-generating IP services. Ellacoya Networks is known for its scalability and functionality, which are essential for creating competitive service offerings in large carrier IP networks. Headquartered in Merrimack, New Hampshire, the company also maintains offices in London, Tokyo, and Singapore, positioning itself as a key player in the broadband optimization sector.

Brainshark is a prominent sales enablement company based in Waltham, Massachusetts, founded in 1999 by Joe Gustafson. The company specializes in providing software solutions that enhance sales productivity through dynamic content creation, on-demand training, and performance coaching. Its cloud-based platform allows businesses to create, share, and track online and mobile video presentations, equipping sales teams with the necessary tools for effective buyer interactions. Brainshark's offerings enable organizations to improve communication, education, and engagement with their client-facing teams. With a focus on data-driven insights, the company helps clients measure the effectiveness of their sales content and make informed decisions. Thousands of companies, including a significant portion of the Fortune 100, utilize Brainshark's services to boost sales readiness and maximize the impact of their sales, marketing, and training initiatives.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

Revivio, Inc. specializes in continuous data protection solutions for enterprises. Founded in 2001 and based in Lexington, Massachusetts, the company offers a range of products designed to ensure data integrity and availability. Its flagship offering, the Continuous Protection System, allows organizations to restore data instantly and recover critical business applications, effectively eliminating traditional backup windows. The system's capabilities enable users to access data as it existed at various points in time, facilitating rapid recovery in the event of data loss, corruption, or disaster. Additionally, the Continuous Protection System Replication Module extends these benefits to remote sites, helping companies meet stringent disaster recovery requirements. Revivio was acquired by Symantec Corp. in 2006.